Purpose Peripheral neuropathy is an important, yet poorly studied, side effect of pediatric cancer treatment. There are many measures of patient-reported peripheral neuropathy in adults but very few in children. We aimed to systematically review and summarize reliable and valid patient-reported peripheral neuropathy scales used in pediatrics. Methods Four major electronic databases (Medline, Embase, EBSCO Host in Cumulative Index to Nursing and Allied Health Literature, and PsycINFO) were reviewed for studies that measured peripheral neuropathy in pediatric patients. Studies eligible for inclusion were those that described use of any patient-reported scale of peripheral neuropathy among children, adolescents, and young adults with any underlying diagnosis (not limited to cancer).
Introduction
Children who undergo chemotherapy for the treatment of their cancer can experience toxicities from their therapy. Chemotherapy-induced peripheral neuropathy (CIPN) is an important toxicity of several commonly used pediatric cancer medicines, including vincristine and cisplatin [1] . CIPN may manifest in any of the three elements of the peripheral nervous system: sensory, motor, or autonomic. Symptoms of CIPN include numbness, tingling, loss of proprioception, pain, weakness, disco-ordination, and change in thermoregulation, blood pressure, and intestinal mobility. These symptoms may be cumulative and progressive and can have both an immediate and long-term impact on overall quality of life and physical function [2] [3] [4] [5] . Up to 40 % of testicular cancer survivors suffer from persistent long-term CIPN [5] , and over one third of ovarian tumor survivors also suffer from persistence of CIPN [4] .
Objective measures of CIPN (e.g., nerve conduction studies) are rarely feasible or cost-effective to conduct on largescale studies, and they are often unpleasant to administer. In many clinical studies, the Common Terminology Criteria for Adverse Events (CTCAE) are used to report toxicities, but they have been shown to under-report the incidence of CIPN by up to 40 % [6] [7] [8] . Comprehensive clinical neurological exams tend to be poorly reproducible, inconsistent, or incomplete in their assessment of CIPN [7] .
Patient-reported outcomes (PROs) measure symptoms and signs from the patient perspective and thus are a measure of the impact of therapies from the patient's perspective. They are an important adjunct to objective measure to determine how the symptom affects the patient's quality of life. Uncertainty regarding available, validated instruments to measure PROs of peripheral neuropathy in children, adolescents, and young adults with cancer led us to undertake a systematic review of all patientreported outcome tools to measure peripheral neuropathy in this age range. Adolescents and young adults (AYAs) are a particularly disadvantaged group in terms of understanding of PROs as there are very few instruments that span the AYA age range [9] . Our objectives were to identify studies that describe validated patient-reported scales of peripheral neuropathy in children, adolescents, and young adults.
Methods
Data sources and electronic searches We utilized the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations for this systematic review [10] .
A medical librarian developed and executed our electronic searches using the Ovid search platform in the following databases: Medline (1946-), Embase (1947-), EBSCOHost in Cumulative Index to Nursing and Allied Health Literature (CINAHL) (1981-), and PsycINFO (1806-) from their inceptions up to August 2015. We used the medical subject headings and text words specific to each database to identify pediatric, adolescent, or young adult patients combined with peripheral neuropathy terms. The full search strategy is in Appendix 1.
Study selection
The inclusion and exclusion criteria were defined a priori. Inclusion criteria were studies that used any patient-reported scale of peripheral neuropathy among children, adolescents, and young adults with any underlying diagnosis (not limited to cancer). The exclusion criteria were as follows: the study population did not include anyone under the age of 18 years, the neuropathy measure was not patient reported, the study only included clinician reported or objective measures, the study only evaluated physiological measures of neuropathy (e.g., nerve conduction studies, biothesiometry), the study was a non-English publication, the publication was not full text (e.g., conference proceedings, dissertations), or the study was a case report or review.
Data abstraction Two reviewers (DJ and AR) independently identified the titles and abstracts of studies identified by the search strategies. Potentially eligible studies were evaluated at full text. They applied the inclusion and exclusion criteria, and final inclusion of studies into the systematic review was by agreement of both reviewers.
The same two reviewers then abstracted all data in duplicate and discrepancies were resolved by consensus. Data were abstracted with a common case report instrument, developed prior to data collection based on study objectives. The variables of interest from the studies were year of publication, study dates, country of study population, languages, name of the tool to measure neuropathy and description of the scale, recall period for neuropathy symptoms, how the PRO was completed, age of participant, medication used in study population, number of participants enrolled, who completed the PRO instrument, timing of assessment, number of assessments, and any psychometric evaluation. We abstracted published data only; no authors were contacted to obtain additional or unreported information.
Participation bias and analysis bias examined whether the study may have been affected by selection bias and confounding, respectively. These elements were rated as being at low, medium, or high risk of bias based upon the recruited patient group and the associations examined, based on the abstractor's judgment [11] . Discrepancies in bias assessments were resolved by consensus. All included studies were included in qualitative descriptive analyses.
Results
From a total of 765 articles retrieved, 718 were excluded based on title and abstract. Forty-seven full text articles were screened for full inclusion and exclusion criteria and 42 were excluded; 4 were not conducted with pediatric patients, 17 did not include patient-report, 12 were conference proceedings, and 6 were duplicate articles. A total of 5 full text articles met eligibility criteria and were included [6, 8, [12] [13] [14] . Figure 1 demonstrates the flow for article identification and selection.
Details of the 5 included articles of patient-reported outcomes of neuropathy in patients under the age of 18 years are in Table 1 . Four of the articles utilized a modified form of the total neuropathy score (TNS) in pediatric oncology patients; three of these were published by the same authors. We were unable to determine if there were overlapping patients included in the three studies. The final paper utilized the neuropathy symptom score in pediatric diabetes patients.
Pediatric modified total neuropathy score
The three articles utilizing a modified TNS use a scale called the Bpediatric modified total neuropathy score^(Ped-mTNS) [6, 12, 14] . This scale uses a scripted questionnaire for sensory symptoms of tingling, numbness or hurt, functional symptoms of buttoning, walking and going up stairs, and autonomic symptoms of dizziness or hot or cold hands or feet. If there is a yes response to any of these neuropathies, then they are rated on a 0-4 scale. The Ped-mTNS also has 5 clinical testing domains: light touch sensation, pin sensibility, vibration sensibility, strength, and deep tendon reflexes. The Gilchrist 2013 study on the Ped-mTNS included psychometric properties of the scale in patients aged 5 to 18 years [12] . This study tested test-retest reliability by retesting 10 patients by the same investigator and 10 by another investigator with at least 1 h between the tests and no new chemotherapy given in this interval. The overall Cronbach alpha was 0.76, the test-retest intra-class coefficient (ICC) was 0.99 (95 % CI of 0.96-0.99), and inter-rater ICC was 0.98 (95 % CI of 0.95-0.99). Testing of validity showed that the subjects scored significantly worse compared to controls (8.7 to 1.4, p < 0.001).
Total neuropathy score pediatric vincristine
One of the four articles utilizing a modified TNS was the total neuropathy score pediatric vincristine (TNS-PV) [8] . This study measured the worst subjective symptom of tingling, numbness, or neuropathic pain and rated them on a scale from 0 (no symptoms) to 4. It also measured vibration sensibility, temperature sensibility, strength, tendon reflexes, constipation, and hoarseness, also on a 0 to 4 scale by trained evaluators. Neuropathic pain was also measured in this study using the FACES pain scale. The study measured inter-rater reliability by using the scale on the same patient twice in the same day. The Cronbach alpha for the scale as a whole was 0.84 showing internal consistency Fig. 1 Flow diagram of study identification and selection reliability. There was a strong correlation between the TNS-PV score and the total vincristine dose received by the patient.
Neuropathy symptom score
The final article was a patient-reported outcome in diabetic patients aged 8 to 18 years [13] . The neuropathy symptom score asks patients about burning, numbness, tingling, fatigue, cramping, or pain in the legs, nocturnal exacerbation of signs, and any maneuver that reduced the signs. The scoring included detailed neurologic exam as well as nerve conduction studies.
There was no evaluation of reliability, validity, or responsiveness of the scale described in the study.
Discussion
In this systematic review, we identified five articles describing patient-reported outcomes of neuropathy in pediatric and adolescent patients. Four of the five described a pediatric modification of the total neuropathy score, and one study evaluated the Neuropathy Symptom Score. The Neuropathy Symptom Score article did not describe any psychometrics of this instrument that was modified for pediatrics and, thus, cannot be considered a validated scale for measuring neuropathy in pediatrics. The total neuropathy score has been modified for pediatrics in the Ped-mTNS and the TNS-PV. Both scales have a patient-reported component for sensory, functional, and autonomic neuropathy symptoms, as well as an objective component that measures strength, deep tendon reflexes, temperature, and vibration sensitivity and others. The objective measures require fairly extensive assessment and are not overly conducive to all clinical settings. These tools as well have only been used in very small numbers of patients and were administered only after professionals received training on measuring the objective component [8] or by a physiotherapist [6, 12, 14] .
Based on our findings, an instrument consisting solely of a patient-reported neuropathy instrument has not been developed for pediatric populations. As this is a symptom that is known to impact quality of life in survivors of cancer therapy [2, 7, 15] , it is prudent to measure it effectively in the population of patients experiencing this symptom. Among adults, the Gynecologic Oncology Group (GOG) has developed a patient-reported outcome measure for neuropathy (the BFACT/GOG-NTX^) [16] . This measure is a 4-to 13-item PRO measure describing neuropathy symptoms ranging from numbness, tingling, discomfort, weakness, and hearing loss. There are no objective elements in this scale. This may be a promising instrument to evaluate for reliability and validity in a pediatric population as the items appear to be applicable in this age range. If it is not valid and discriminant in the pediatric population, then future work should be undertaken to develop an effective scale for this population. Ultimately, pediatric and adolescent ageappropriate PROs to assess neuropathy may facilitate better understanding of its impact on overall well-being, in turn informing interventions and improving clinical care. 
